Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Atopic dermatitis

Research

Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment

June 2, 2025June 2, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the initiation of a Phase 2 trial for its investigational drug bosakitug (ATI-045), targeting moderate-to-severe atopic dermatitis (AD). This randomized, …

Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment Read More

Aclaris Therapeutics
Research

Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis

September 19, 2024September 17, 2024 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent inhibitor targeting ITK and JAK3, aimed at treating moderate to …

Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis Read More

Trending News

  • Juvenile Arrested on Gun Charges in Wilmington

  • Wilmington Man Arrested on Drug and Firearm Allegations

  • Two Individuals Charged with Filing False Police Reports in Parkesburg

  • Fugitive Taken into Custody in Parkesburg

  • Coatesville Police Investigate Fatal Stabbing

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Arrested

Juvenile Arrested on Gun Charges in Wilmington

July 1, 2025July 1, 2025

Shannon Johnson

Wilmington Man Arrested on Drug and Firearm Allegations

July 1, 2025July 1, 2025

Parkesburg Borough Police Department

Two Individuals Charged with Filing False Police Reports in Parkesburg

July 1, 2025July 1, 2025

Copyright © 2025 MyChesCo.